Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antox is a multi-ingredient antioxidant supplement manufactured by the Arab Drug Company (ADCO) in Egypt. It is formulated as a combination of selenium, beta-carotene (a precursor to Vitamin A), ascorbic acid (Vitamin C), and alpha-tocopherol (Vitamin E). In clinical research, particularly at institutions like Ain Shams University, it has been evaluated as an adjuvant therapy for conditions associated with oxidative stress, such as immune thrombocytopenia (ITP). The supplement aims to neutralize free radicals, reduce lipid peroxidation, and improve the oxidant/antioxidant balance, which may help preserve cell membrane integrity and extend the lifespan of platelets in ITP patients. Each tablet typically contains 50 mcg of selenium, 26.64 mg of beta-carotene, 100 mg of Vitamin C, and 30 mg of Vitamin E.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antox.